Novavax Retained Earnings from 2010 to 2024

NVAX Stock

USD 8.91 0.27 2.94%

Novavax Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Novavax retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

1996-03-31

Previous Quarter

-5 B

Current Value

-4.8 B

Quarterly Volatility

1.3 B

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 97.33. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.

Check out the analysis of Novavax Correlation against competitors.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Novavax over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Novavax's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (4.82 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Novavax Retained Earnings Regression Statistics

	Arithmetic Mean	(1,747,469,563)
	Coefficient Of Variation	(96.99)
	Mean Deviation	1,390,872,618
	Median	(1,114,359,000)
	Standard Deviation	1,694,818,575
	Sample Variance	2872410T
	Range	4.8B
	R-Value	(0.92)
	Mean Square Error	491642.1T
	R-Squared	0.84
	Slope	(347,554,683)
	Total Sum of Squares	40213740T

Novavax Retained Earnings History

	2024	-4.6 B
	2023	-4.8 B
	2022	-4.3 B
	2021	-3.6 B
	2020	-1.9 B
	2019	-1.4 B
	2018	-1.3 B

Other Fundumenentals of Novavax

Retained Earnings Total Equity

Novavax Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Receivables	Intangible Assets	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.56	-0.87	-0.91	0.93	0.96	0.99	0.88	-0.46	0.67	-0.37	0.33	-0.98	0.88	0.76	0.96	-0.24	-0.63	0.47	0.95	-0.21	0.68	-0.42	-0.61	-0.78
Total Stockholder Equity	-0.56		0.4	0.79	-0.72	-0.76	-0.48	-0.4	0.35	-0.06	0.15	-0.19	0.67	-0.74	-0.3	-0.46	0.75	0.99	-0.27	-0.68	0.13	-0.59	0.92	0.93	0.45
Net Debt	-0.87	0.4		0.67	-0.82	-0.8	-0.91	-0.74	0.22	-0.6	0.46	-0.03	0.85	-0.64	-0.85	-0.75	0.25	0.48	-0.17	-0.7	-0.02	-0.33	0.31	0.56	0.57
Retained Earnings	-0.91	0.79	0.67		-0.93	-0.97	-0.85	-0.77	0.5	-0.48	0.28	-0.33	0.95	-0.97	-0.54	-0.89	0.44	0.83	-0.52	-0.98	0.25	-0.79	0.68	0.78	0.77
Accounts Payable	0.93	-0.72	-0.82	-0.93		0.96	0.89	0.68	-0.41	0.65	-0.36	0.17	-0.96	0.93	0.57	0.87	-0.38	-0.77	0.39	0.91	-0.16	0.63	-0.59	-0.82	-0.71
Total Liab	0.96	-0.76	-0.8	-0.97	0.96		0.92	0.82	-0.47	0.54	-0.34	0.32	-0.98	0.93	0.69	0.9	-0.44	-0.81	0.46	0.96	-0.21	0.72	-0.63	-0.78	-0.76
Total Current Assets	0.99	-0.48	-0.91	-0.85	0.89	0.92		0.87	-0.45	0.72	-0.38	0.36	-0.95	0.8	0.83	0.93	-0.2	-0.57	0.47	0.89	-0.21	0.63	-0.32	-0.54	-0.76
Net Receivables	0.88	-0.4	-0.74	-0.77	0.68	0.82	0.87		-0.38	0.41	-0.43	0.31	-0.85	0.74	0.78	0.87	-0.18	-0.45	0.34	0.85	-0.14	0.6	-0.34	-0.36	-0.72
Intangible Assets	-0.46	0.35	0.22	0.5	-0.41	-0.47	-0.45	-0.38		-0.32	0.08	-0.53	0.44	-0.43	-0.29	-0.52	-0.09	0.36	-0.64	-0.53	0.53	-0.59	0.22	0.28	0.49
Short Term Debt	0.67	-0.06	-0.6	-0.48	0.65	0.54	0.72	0.41	-0.32		-0.34	0.37	-0.61	0.49	0.43	0.69	0.11	-0.18	0.35	0.55	-0.15	0.47	0.21	-0.18	-0.6
Common Stock	-0.37	0.15	0.46	0.28	-0.36	-0.34	-0.38	-0.43	0.08	-0.34		0.09	0.43	-0.3	-0.33	-0.34	0.23	0.2	0.25	-0.32	-0.27	-0.14	0.05	0.17	0.63
Long Term Debt	0.33	-0.19	-0.03	-0.33	0.17	0.32	0.36	0.31	-0.53	0.37	0.09		-0.24	0.15	0.37	0.36	-0.07	-0.25	0.67	0.35	-0.47	0.68	0.11	0.03	-0.48
Treasury Stock	-0.98	0.67	0.85	0.95	-0.96	-0.98	-0.95	-0.85	0.44	-0.61	0.43	-0.24		-0.93	-0.7	-0.93	0.36	0.73	-0.39	-0.96	0.15	-0.67	0.54	0.72	0.77
Property Plant Equipment	0.88	-0.74	-0.64	-0.97	0.93	0.93	0.8	0.74	-0.43	0.49	-0.3	0.15	-0.93		0.41	0.89	-0.35	-0.75	0.4	0.96	-0.18	0.68	-0.67	-0.76	-0.69
Current Deferred Revenue	0.76	-0.3	-0.85	-0.54	0.57	0.69	0.83	0.78	-0.29	0.43	-0.33	0.37	-0.7	0.41		0.63	-0.23	-0.4	0.31	0.58	-0.12	0.41	-0.17	-0.33	-0.54
Good Will	0.96	-0.46	-0.75	-0.89	0.87	0.9	0.93	0.87	-0.52	0.69	-0.34	0.36	-0.93	0.89	0.63		-0.13	-0.52	0.51	0.96	-0.21	0.73	-0.33	-0.49	-0.81
Short Term Investments	-0.24	0.75	0.25	0.44	-0.38	-0.44	-0.2	-0.18	-0.09	0.11	0.23	-0.07	0.36	-0.35	-0.23	-0.13		0.77	0.22	-0.31	-0.4	-0.38	0.66	0.65	0.29
Net Tangible Assets	-0.63	0.99	0.48	0.83	-0.77	-0.81	-0.57	-0.45	0.36	-0.18	0.2	-0.25	0.73	-0.75	-0.4	-0.52	0.77		-0.29	-0.72	0.11	-0.65	0.86	0.93	0.53
Long Term Debt Total	0.47	-0.27	-0.17	-0.52	0.39	0.46	0.47	0.34	-0.64	0.35	0.25	0.67	-0.39	0.4	0.31	0.51	0.22	-0.29		0.53	-0.82	0.62	-0.15	-0.23	-0.47
Capital Surpluse	0.95	-0.68	-0.7	-0.98	0.91	0.96	0.89	0.85	-0.53	0.55	-0.32	0.35	-0.96	0.96	0.58	0.96	-0.31	-0.72	0.53		-0.26	0.79	-0.57	-0.67	-0.81
Deferred Long Term Liab	-0.21	0.13	-0.02	0.25	-0.16	-0.21	-0.21	-0.14	0.53	-0.15	-0.27	-0.47	0.15	-0.18	-0.12	-0.21	-0.4	0.11	-0.82	-0.26		-0.33	0.07	0.09	0.17
Short Long Term Debt	0.68	-0.59	-0.33	-0.79	0.63	0.72	0.63	0.6	-0.59	0.47	-0.14	0.68	-0.67	0.68	0.41	0.73	-0.38	-0.65	0.62	0.79	-0.33		-0.36	-0.43	-0.77
Net Invested Capital	-0.42	0.92	0.31	0.68	-0.59	-0.63	-0.32	-0.34	0.22	0.21	0.05	0.11	0.54	-0.67	-0.17	-0.33	0.66	0.86	-0.15	-0.57	0.07	-0.36		0.9	0.26
Net Working Capital	-0.61	0.93	0.56	0.78	-0.82	-0.78	-0.54	-0.36	0.28	-0.18	0.17	0.03	0.72	-0.76	-0.33	-0.49	0.65	0.93	-0.23	-0.67	0.09	-0.43	0.9		0.41
Capital Stock	-0.78	0.45	0.57	0.77	-0.71	-0.76	-0.76	-0.72	0.49	-0.6	0.63	-0.48	0.77	-0.69	-0.54	-0.81	0.29	0.53	-0.47	-0.81	0.17	-0.77	0.26	0.41

Click cells to compare fundamentals

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-4.8 B	-4.6 B
Retained Earnings Total Equity	-3.3 B	-3.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC